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ABSTRACT
Objective: To determine the feasibility, acceptability, dis-
criminative validity, responsiveness, and minimal important
difference (MID) of the SF-6D for people with spinal cord
injury (SCI).
Methods: A total of 305 people with SCI completed the
SF-36 health status questionnaire at baseline and at subse-
quent occurrence of a urinary tract infection (UTI) or
6-month follow-up. Normative SF-36 data were obtained
from the Australian Bureau of Statistics. SF-36 scores were
transformed to SF-6D utility values using Brazier’s algorithm.
We used UTI as the external criterion of clinically important
change to determine responsiveness and two categories of the
SF-36 transition question (“somewhat worse” and “some-
what better”) as the external criterion to determine the MID.
Derived SF-12 responsiveness was also assessed.
Results: The mean SF-6D values were: 0.68 (SD 0.21,
n = 305) all patients; 0.66 (SD 0.19, n = 167) tetraplegia;
0.72 (SD 0.26, n = 138) paraplegia; 0.57 (SD 0.15, n = 138)
with UTI. The Australian normative SF-6D mean value was
0.80 (SD 0.14, n = 18,005). The SF-6D was able to discrimi-
nate between SCI and the Australian normative sample
(effect size [ES] = 0.86), tetraplegia–paraplegia (ES = 0.23),
and it was responsive to UTI (ES = 0.86 SF-36 variant,
ES = 0.92 SF-12 variant). The MID for respondents who
reported being somewhat worse or somewhat better at
follow-up was 0.03 (SD 0.17, n = 108/305), while the MID
for only those who were somewhat worse was 0.10 (SD 0.14,
n = 58).
Conclusions: The content of the SF-6D is more appropriate
than that of the SF-36 for this physically impaired popula-
tion. The SF-6D has discriminative power and is responsive
to clinically important change because of UTI. The MID is
consistent with published estimates for other disease
groups.
Keywords: health economics, health preference state, SF-6D,
spinal cord injury, urinary tract infection, validity.
Introduction
Preference-based measures of health allow the relative
value of health states to be compared, both within and
across diseases [1]. A fundamental concept underpin-
ning this is health utility [2], a measure of preference
for health outcomes. Combined with survival data,
utilities can be used to estimate quality-adjusted life-
years (QALYs). Utilities and QALYs are used in cost-
utility analyses to assess the relative value of health
interventions, across a range of purposes (preventive,
diagnostic, curative, palliative), types (programs, ser-
vices, technologies, pharmaceuticals), and populations
(within and across diseased, disabled, and healthy
populations). Preference-based measures are therefore
useful and important outcome measures for policy-
makers, both locally and internationally.
The SF-6D, a relatively new utility measure, is par-
ticularly attractive as it is calculated from the SF-36, a
health status measure commonly used to assess the
impact of disease and disability, including spinal injury
[3]. In common with other multiattribute utility instru-
ments such as EQ-5D (Euroqol) and Health Utilities
Index (HUI) [4], it allows those experiencing the health
states to contribute directly to utility scores. A particu-
lar advantage of the SF-36 and SF-6D is that they
economize on data collection, yielding measures of
both health status and utility. Since the SF-6D meth-
odology was published 5 years ago, it has rapidly
become a popular method of utility estimation. A
recent systematic review of the use of heath status
measurement instruments to calculate QALYs found
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that, despite its contemporary origin, the SF-6D
accounted for 5% of the instruments used [5].
The SF-6D is a utility measure based on a six-
dimensional health state classiﬁcation. It is derived
from a subset of 11 SF-36 questions covering the
dimensions of Physical Functioning, Role Limitation,
Social Functioning, Pain, Mental Health, and Vitality.
It allows a possible 18,000 health states to be deﬁned.
A survey (involving SF-6D, ranking, and standard
gamble) of 249 health states deﬁned by the SF-6D was
valued by a representative sample of the UK general
public (n = 611). Econometric methods were then used
to determine a model for predicting the standard
gamble scores generated by the valuation survey [6].
Brazier et al. have shown that the SF-6D is a viable
alternative preference measure [6]. It can be derived
from either the SF-36 [6] or the shorter SF-12 [7]. It
has been suggested that the SF-6D may be more sen-
sitive than the EQ-5D, especially for mild–moderate
health issues [6]. Limitations and outstanding issues
with the SF-6D include whether it compromises the
richness of the original SF-36 [6] and whether it is less
sensitive when used in poorer health states [6,8,9]. It is
therefore important that additional validation studies
are performed in different populations and settings.
The present article describes such a validation in an
Australian population with spinal cord injury (SCI),
most of whom were living in a general community
setting.
The minimal important difference (MID) allows cli-
nicians to determine whether a change observed on a
self-reported health rating scale is meaningful or
trivial. It has been deﬁned as the smallest difference in
score that the patient perceives as beneﬁcial [10]. For
our purposes, in the absence of signiﬁcant side effects
or cost barriers, this would lead to a change in clinical
decision-making.
This article provides the ﬁrst validation and MID
values for the SF-6D in the SCI population. We assess
the acceptability and appropriateness of the SF-6D for
application in SCI, evaluate its discriminative ability,
and determine its responsiveness to clinically impor-
tant change. The external criterion used to deﬁne clini-
cally important change is the occurrence of a urinary
tract infection (UTI), a common comorbidity in this
patient population group, with a reported incidence of
1.82 episodes per annum [11,12].
Methods
Data were collected during the Spinal-Injured Neuro-
pathic Bladder Antisepsis randomized controlled trial
[13]. Subjects were sampled from the New South
Wales (State) Spinal Cord Injuries Database [14] and
related databases of two major teaching hospitals.
Inclusion criteria were: SCI with neurogenic bladder;
stable bladder management; absence of serious renal
pathology; not taking antibiotics at enrollment; and
absence of symptoms of a UTI at enrollment. Between
November 2000 and August 2002, 543 eligible
patients (predominantly community dwelling) were
invited to participate in the study, of whom 305 (56%)
agreed. Characteristics of the sample and reasons for
nonparticipation are reported elsewhere [13].
Subjects completed the SF-36 at enrollment and
again on development of UTI. If no UTI was experi-
enced, a repeat SF-36 was completed at 6-month
follow-up. Subjects completed the SF-36 by self-report
with a research ofﬁcer present, or by self-report via
mail. Incomplete responses or inconsistencies were
clariﬁed by direct inquiry. Interpreters and physical
assistance were used where necessary.
The SF-6D utility and dimensional scores were
derived from SF-36 responses using Brazier’s algo-
rithm [6]. The domains and SF-36 items [15] used to
construct the SF-6D were: Physical Functioning (items
3a, 3b, and 3j); Role Limitation due to physical prob-
lems (item 4c) and Role Limitation due to emotional
problems (item 5b); Social Functioning (item 10); both
bodily pain items (items 7 and 8); Mental Health
(items 9b and 9f); and Vitality (item 9e). To explore
whether the SF-12 version of the SF-6D differed in
responsiveness from the full SF-36 version, SF-6D
utility scores were recalculated using the Brazier SF-12
algorithm [7] for the responsiveness analysis.
Acceptability and appropriateness were assessed in
terms of feasibility and content validity. Practical dif-
ﬁculties in the use of the SF-36 or content issues iden-
tiﬁed by subjects, research assistants, or authors during
administration were recorded. Ceiling and ﬂoor effects
for each SF-6D domain were examined by neurological
level of injury (tetraplegia vs. paraplegia) [16].
Discriminative validity was assessed with cross-
sectional comparisons of mean SF-6D utility and
dimensional scores, externally by comparing the SCI
patients with Australian normative data, and inter-
nally by comparing various subgroups of the SCI
patients. Normative Australian SF-36 data were from
18,005 respondents in the Australian Bureau of Statis-
tics National Health Survey of 1995 [17]. Means and
standard deviations for normative and sample data
were adjusted to ﬁt the age and sex distribution of the
Australian population using direct standardization
[18].
Internal cross-sectional comparisons were based on
a priori hypotheses made by three experts, one in
rehabilitation medicine (BL) and two in quality-of-life
research (MK, MS), who independently ranked their
expectations about the size and direction of differences
in SF-36 scales between groups deﬁned by six clinically
relevant variables. When applied to the single SF-6D
index score, these led to six a priori hypotheses about
the derived utility scores: that more (vs. less) extensive
neurological level, more (vs. less) completeness of
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injury, older (vs. younger) age, unemployment (vs.
employment), being female (vs. male), and more (vs.
less) recent injury would be associated with lower
(vs. higher) utility scores. Further, the experts predicted
that the mean differences in SF-6D utility scores
between groups dichotomized by neurological level,
completeness of injury, age, and employment status
would be larger than those between groups dichoto-
mized by sex and time since injury, and that effect sizes
(ES) for the former set of characteristics would be
small to moderate (0.2–0.5) while those for the latter
would be at best small (<0.2).
Mean differences in SF-6D scores between groups
were tested using t-tests for independent samples. For
between-group comparisons, ES were calculated fol-
lowing the method of Kazis et al. [19]: ES = (m1 - m2)/
s1, where m1 is reference group mean, m2 is comparison
mean, and s1 is reference group standard deviation.
The responsiveness of the SF-6D to clinically rel-
evant change in health status was determined in the
138 patients who developed a UTI during the course of
the clinical trial. The mean change in the SF-6D utility
score from the ﬁrst to the second assessment was cal-
culated for scores based on both the SF-36 and SF-12
algorithms. For within-group comparisons, we used
the longitudinal form of ES (mean change/standard
deviation of change), also called the standardized
response mean [7].
The MID was calculated using the method of
Walters and Brazier as follows [20]. The health tran-
sition item (Question 2) of the SF-36 (which is not part
of the SF-6D) was used to deﬁne respondents who had
experienced a MID. This question asks “Compared to
1 year ago, how would you rate your health in general
now?”, with ﬁve response options: 1 = much worse,
2 = somewhat worse, 3 = about the same, 4 = some-
what better, and 5 = much better. A score of “2” or
“4” was deemed equivalent to the MID. Where
patients reported a worsening of health, the sign of the
SF-6D score change was reversed before combining
with those patients who reported improvement. Our
methodology differed from Walter and Brazier’s in one
crucial respect: our questionnaire used the original
SF-36 Question 2, which compares health now to
1 year ago, whereas they modiﬁed the comparison
time frame to be consistent with the duration of
follow-up [20].
The trial was approved by the ethics committees of
the participating hospitals (Royal North Shore Hospi-
tal, Prince of Wales Hospital, Prince Henry Hospital,
and Royal Rehabilitation Center Sydney). All compu-
tations and statistical tests were conducted in SAS
version 9 (SAS Institute Inc., Cary, NC, USA).
Results
Trial participants had a longer mean time since SCI (by
2.6 years) than those who were excluded or did not
consent. There were no other signiﬁcant differences
between participants and nonparticipants [13].
Participants had a mean age of 44 years (SD 14,
range 16–82 years) and were predominantly male
(83%). Fifty-ﬁve percent of patients had tetraplegia
and 49% had a complete spinal injury. The median
time since SCI was 12 years (range from 1 month to
61 years). The characteristics used to deﬁne subgroups
for assessing discriminative validity are presented in
Table 1.
Table 1 Baseline characteristics of 305 patients with spinal cord injury categorized by criteria used to assess discriminative validity,
mean SF-6D scores for each subgroup, differences between groups, and effect sizes
Characteristics n % Mean* (SD) Difference (P-value†) Effect size‡
Neurological level
Tetraplegia 167 55 0.68 (0.13) 0.05 (0.002) 0.34
Paraplegia§ 138 45 0.73 (0.15)
Completeness
Complete (ASIA A) 148 49 0.72 (0.15) -0.02 (0.18) -0.16
Incomplete (ASIA B–D)§ 157 51 0.69 (0.14)
Age (year)
16–43§ 157 51 0.70 (0.15) -0.01 (0.83) -0.02
44+ 148 49 0.71 (0.14)
Employment (hour)
No paid 197 65 0.68 (0.15) 0.05 (0.002) 0.40
Any paid§ 108 35 0.74 (0.14)
Sex
Male§ 252 83 0.71 (0.14) 0.04 (0.08) 0.27
Female 53 17 0.67 (0.15)
Time since injury (year)
4 years 90 30 0.68 (0.15) 0.04 (0.04) 0.26
>4 years§ 215 70 0.71 (0.14)
*Mean SF-6D score for each subgroup at recruitment, not adjusted to the age and sex distribution of the Australian population. Higher scores reﬂect better health.
†t-test for independent samples.
‡Effect size calculated following the method of Kazis et al. [19].
§Reference Group.
ASIA,American Spinal Injuries Association Neurological Classiﬁcation [16].
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Feasibility and Content Validity
There were no missing data. Issues about the content
of the SF-36 raised by participants included: uncer-
tainty if limitations of activities referred to a compari-
son with a non-SCI person or the patient’s usual
activities; problems with physical activity questions
(particularly those involving walking or climbing
stairs), and uncertainty about the period of recall
required.
Ceiling and Floor Effects
The full range of levels was observed for all six dimen-
sions of the SF-6D. Table 2a shows the results for the
overall sample and stratiﬁed by neurological level. An
apparent ﬂoor effect (37%) in the Physical Functioning
dimension in the overall sample was accounted for
almost entirely by the tetraplegia group (63%). In
contrast, there were no notable ﬂoor effects in the
Australian sample (Table 2b). Ceiling effects in the SCI
sample (27–56%) occurred in the Role Limitation,
Social Functioning, Pain, and Mental Health dimen-
sions, irrespective of neurological category. Ceiling
effects were also apparent in the normative sample,
exceeding those in the SCI sample for Role Limitation
(70% vs. 55%) and Social Functioning (63% vs.
50%), but interestingly less so for Mental Health
(20% vs. 35%).
Discriminative Validity
Figure 1 shows mean scores for each of the six SF-6D
dimensions for subjects with SCI (tetraplegia and
paraplegia), compared to a large normative Australian
population sample. The ES for overall utility (Table 3)
express the degree of discrimination in the SF-6D
index scores between the Australian norms and the SCI
sample (ES = 0.86, P < 0.0001) and between paraple-
gic and tetraplegic subgroups (ES = 0.23, P = 0.025).
Dissecting the SF-6D index into its six component
domains (Table 3), we see the most pronounced differ-
ences in the Physical Functioning dimension, with
paraplegic patients being clearly worse than the nor-
mative sample and the tetraplegic patients being
demonstrably the worst group. The other dimensions
(Role Limitation, Social Functioning, Pain, Mental
Health, and Vitality) showed relatively small absolute
differences and ES compared to the Physical Function-
ing dimension.
Table 1 shows the mean SF-6D utility scores for
groups dichotomized by six clinically relevant baseline
characteristics. Differences in mean SF-6D scores were
in the direction expected with the exception of com-
Table 2 Proportion of responses (%) on each level* of the SF-6D dimensions in (a) the sample of SCI individuals and (b) theAustralian











(a) Sample of SCI individuals
All SCI (n = 305)
1 6 55 50 36 35 5
2 9 25 18 20 26 40
3 14 7 12 18 27 31
4 24 13 12 13 10 14
5 10 — 8 10 2 10
6 37 — — 4 — —
Tetraplegia (n = 167)
1 2 54 51 43 34 4
2 1 27 18 19 27 40
3 5 8 13 14 28 28
4 20 11 11 11 9 16
5 10 — 7 11 2 12
6 63 — — 2 — —
Paraplegia (n = 138)
1 11 56 50 27 38 6
2 18 22 18 21 24 41
3 26 6 10 22 26 36
4 30 17 13 16 11 12
5 10 — 9 9 1 7
6 5 — — 6 — —
(b) Australian normative sample
1 45 70 63 39 20 8
2 30 10 19 25 38 54
3 13 11 12 21 31 27
4 6 9 5 8 8 8
5 3 — 2 6 2 3
6 3 — — 2 — —
*Two dimensions have six levels (Physical Functioning, Pain); three dimensions have ﬁve levels (Social Functioning, Mental Health,Vitality); one dimension has only four levels (Role
Limitation). Level 1 represents the best health (ceiling) and the highest level represents the worst health (ﬂoor).
SCI, spinal cord injury.
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pleteness of injury and age. ES were generally as
expected, although those for sex and time since injury
were larger than expected and those for age and com-
pleteness of injury were smaller than expected. Statis-
tically signiﬁcant differences were found only for
neurological level, employment, and time since injury.
Responsiveness
For the 138 trial participants who developed UTI, the
overall age- and sex-adjusted utility score was 0.68
(SD 0.20) before and 0.57 (SD 0.15) after UTI. Table 4
presents unadjusted results for those who developed
UTI, which demonstrate the responsiveness of the
SF-6D to this common and clinically signiﬁcant comor-
bidity. Corresponding results for the 167 trial partici-
pants who did not develop UTI show the extent to
which SF-6D utility scores change over a 6-month
period in a SCI sample whose health is stable (Table 4).
The larger absolute differences and ES in the former
group and the small absolute differences and ES in the
latter group conﬁrm the responsiveness of SF-6D.
Figure 2 decomposes the utility index into its six com-
ponent domains, showing that the subjects who devel-























Figure 1 SF-6D proﬁles for tetraplegic
(n = 138) and paraplegic patients (n = 167) com-
pared to a normative Australian population
sample (n = 18,005): all values are means
adjusted for the age and sex distribution of the
Australian population. A higher score repre-
sents worse health. The range of scores is
as follows: SFPhys (Physical Functioning) 1–6,
SFRole (Role Limitation) 1–4, SFSocial (Social
Functioning) 1–5, SFPain (Pain) 1–6, SFMental
(Mental Health) 1–5, SFVital (Vitality) 1–5.
Table 3 SF-6D scores for (a) a normativeAustralian population sample (n = 18,005) and the SCI sample (n = 305) and (b) a paraplegic





Mean (SD) Effect size||
Overall utility* 0.80 (0.14) 0.68 (0.21) 0.86
SFPhysical 2.03 (1.20) 4.34 (1.94) 1.93
SFRole 1.61 (1.01) 1.91 (1.44) 0.30
SFSocial 1.64 (0.99) 2.17 (2.03) 0.54
SFPain 2.23 (1.28) 2.70 (2.24) 0.20
SFMental 2.34 (0.97) 2.32 (1.76) -0.02





Mean (SD) Effect size||
Overall utility* 0.72 (0.26) 0.66 (0.19) 0.23
SFPhysical 3.33 (1.72) 5.25 (1.54) 1.12
SFRole 1.96 (1.80) 1.87 (1.44) -0.05
SFSocial 2.20 (2.23) 2.13 (2.09) -0.03
SFPain 2.86 (2.66) 2.51 (2.17) -0.13
SFMental 2.15 (1.76) 2.42 (1.61) 0.15
SFVitality 2.73 (1.65) 3.03 (1.67) 0.18
*Overall utility: higher score is better (where 1 = perfect health and 0 = death). Signiﬁcance test for overall utility: 2 sample t-test P < 0.0001 (a) and P = 0.025 (b).
†SF-6D mean dimension levels: higher score is worse.
‡Adjusted to the age and sex distribution of the Australian population.
§Reference group.
||Effect size calculated following the method of Kazis et al. [19].
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every dimension except physical after UTI relative to
before they developed a UTI. Table 4 also shows that
SF-6D utility values calculated using the Brazier SF-12
algorithm are as responsive as those calculated using
the Brazier SF-36 algorithm.
Minimal Important Difference
The MID had a mean value of 0.03 (n = 108; SD 0.17).
When limited to those who were somewhat better, the
MID was -0.04 (n = 50; SD 0.16), and when limited to
those who were somewhat worse, the MID was 0.10
(n = 58; SD 0.14). The difference between the MIDs
of these two groups was statistically signiﬁcant
(P < 0.0001). Of the group who were somewhat
worse, most of the patients (39/58) suffered a UTI. In
interpreting these MIDs, we note that patients who
developed a UTI had a mean follow-up period of
64 days, compared to 182 days for those who did not
develop a UTI; these are less than the 1-year recall
period speciﬁed in the SF-36 health transition question
used as the external criterion for determining the MID.
Discussion
This report validates the SF-6D in a group of patients
with SCI, predominantly living in the general commu-
nity and participating in a randomized trial. It docu-
ments utility values and comparisons with a normative
population, and demonstrates that both the SF-36 and
SF-12 variants of the SF-6D were responsive to clini-
cally important changes in disease state in a group with
severe physical impairment. The SF-36 data were
easily collected by a research assistant. The exclusion
of several SF-36 physical activity questions, particu-
larly those about walking or climbing stairs, which are
problematic for people with SCI, may make the SF-6D
Table 4 Responsiveness of SF-6D* assessed in subjects before and after developing a UTI; subjects who did not develop UTI during
the study serve as controls
Developed UTI (n = 138) Did not develop UTI (n = 167)
SF-12† (SD) SF-36‡ (SD) SF-12† (SD) SF-36‡ (SD)
Mean SF-6D score*
Baseline§ 0.72 (0.14) 0.70 (0.14) 0.72 (0.14) 0.71 (0.15)
Follow-up|| 0.60 (0.12) 0.58 (0.12) 0.70 (0.14) 0.68 (0.15)
Mean change in SF-6D -0.12 (0.13) -0.12 (0.14) -0.02 (0.14) -0.03 (0.14)
Effect size¶ 0.92 0.86 0.14 0.21
*Overall utility: higher score is better (1 = perfect health, 0 = death); not adjusted to the age and sex distribution of the Australian population.
†SF-6D derived from SF-12 scoring algorithm.
‡SF-6D derived from SF-36 scoring algorithm.
§Baseline assessments were at recruitment all subjects.
||For subjects who developed UTI, follow-up assessments were completed on development of UTI. For subjects who did not develop UTI, follow-up assessments were completed
6 months after recruitment.
¶Longitudinal effect size for change is the standardized response mean.






















Figure 2 Responsiveness: SF-6D proﬁles for
spinal cord injured patients (n = 138) before
and after developing urinary tract infection
(UTI): all results are mean values for each
dimension with 95% conﬁdence intervals dis-
played, adjusted for the age and sex distribution
of the Australian population. A higher score
represents worse health.The range of scores is
as follows: SFPhys (Physical Functioning) 1–6,
SFRole (Role Limitation) 1–4, SFSocial (Social
Functioning) 1–5, SFPain (Pain) 1–6, SFMental
(Mental Health) 1–5, SFVital (Vitality) 1–5.
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more acceptable to the SCI population. The SF-6D was
able to discriminate between the SCI sample and the
general population and also between tetraplegic and
paraplegic patients, but it was unable to detect the
differences among people with SCI according to neu-
rological completeness.
The strengths of this study include the perfect
completion rate of the study instrument and the well-
deﬁned cohort sampled from a comprehensive register.
A limitation of this study is that the sample was
derived from a randomized controlled trial targeting
participants with SCI and neurogenic bladder. Com-
pared to the overall New South Wales SCI population,
sample characteristics which may bias toward poorer
utility assessments include the trial’s inclusion criterion
of neurogenic bladder [21] and older age. On the other
hand, the community-based nature of this sample may
bias the results toward better utility scores. Employ-
ment levels (35%) were within the published range for
this population group [22]. In common with other
clinical trials, voluntary participants tend to be more
motivated than nonparticipants [23].
The SF-6D differs markedly from the underlying
SF-36, in that the physical function questions that
relate speciﬁcally to walking and stair climbing are
omitted (SF-36 items 6, 7, 9–11). This redresses a
major problem of the SF-36 in this patient population,
where these questions are seen to be ambiguous or
irrelevant for SCI individuals. SCI researchers are
therefore justiﬁed in questioning the appropriateness
and validity of the standard SF-36 for assessing the
health status in this population [3,24–26]. Although
the SF-6D seems to overcome this issue, the problem
remains whether to obtain data for the SF-6D via the
standard SF-36. There are several responses to this
problem: researchers interested in collecting the SF-6D
could use the standard SF-36 or a modiﬁed version of
it (such as modiﬁcations of Meyers, Andresen, or Tate
[26–28]), do both (as we did) or just apply the subset
of questions used to derive the SF-6D dimension levels
and ﬁnal utility score. Meyers and Tate suggest replac-
ing the words “walk” and “climb” with the word
“go,” arguing that this wording allows SCI individuals
to take into account assistive equipment, while main-
taining adequate construct validity [27]. Provided that
the modiﬁcation chosen does not affect the calculation
of the SF-6D, researchers may ﬁnd a modiﬁed SF-36
more acceptable. Using both standard and modiﬁed
scales (in essence asking the problematic physical ques-
tions twice, with modiﬁed wording to maintain com-
patibility) may make people less sensitive to the
problematic questions as they at least have a relevant
response to one of two related questions.
As people adapt to disability, they reconceptualize
their reference of comparison for health states, result-
ing in higher self-reported health ratings than expected
[29]. Utility scores taken soon after the traumatic event
that causes a SCI are likely to be very different to those
taken many years later, as in the majority of our study
sample. When comparisons were made between the
SCI and normative samples, the better than expected
mental dimension (and the little changed role, social,
and vitality scores) for the SF-6D probably reﬂects
this response shift (Fig. 1). Within the SCI sample
(Table 1), time since spinal injury was signiﬁcantly
associated with SF-6D utility scores, with a moderate
ES that was larger than expected. As expected, subjects
with longer time since injury had higher utilities than
those more recently injured, which in part may reﬂect
postaccident adjustment. Such response shift effects
are likely to lead to the mean utility score improving as
time since SCI increases, which could attenuate the
effect of any disease state deterioration.
The Australian normative values calculated to
compare discriminative validity revealed an overall
age- and sex-adjusted utility score of 0.80 (SD 0.14)
from a sample of 18,005 participants. This is very
similar to the value derived by Bharmal and Thomas
[30] in a sample of 11,248 North American partici-
pants: 0.81 (SD 0.18).
When SF-12 and SF-36 variants of the SF-6D were
compared, they yielded similar utility values. This sug-
gests that the SF-36 and SF-12 variants of the SF-6D
are equally responsive, and that the SF-6D of either
derivation is suitable for detecting the clinical change
resulting from a UTI in a population with SCI.
In dissecting the SF-6D index into its six constituent
domains, the Physical Functioning dimension was the
major discriminator between tetraplegia, paraplegia,
and the Australian normative sample, with relatively
little difference seen for the other SF-6D dimensions
(Fig. 1). In contrast, the Physical Functioning dimen-
sion was the least responsive to UTI disease state
change, with relatively large differences being detected
in the other domains: Role Limitation, Social Function-
ing, Pain, Mental Health, and Vitality (Fig. 2). This
is expected as UTI would not be likely to shift signiﬁ-
cantly a physical score already subject to ﬂoor effects,
particularly in the 55%of participants with tetraplegia.
In contrast, the other dimensions either had ceiling
effects or had room to deteriorate in response to a UTI.
Given that the SF-6D is designed to be used as a single
index of utility, this differential response across the
dimensions is not a problem, and may indeed allow
ﬂexibility of use in other populations.
Walters and Brazier found that the SF-6D MID for
11 disease groups ranged from 0.011 to 0.097 with a
mean of 0.041. The MID for SCI with UTI disease
state change from this study (0.03, SD 0.17) is con-
sistent with these previous estimates. It is important
to note that the results from the two groups used to
calculate the MID (“somewhat worse” and “some-
what better”) were signiﬁcantly different in our
sample. Our questionnaire used the original SF-36
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Question 2, which compares health now with 1 year
ago, while Walters and Brazier modiﬁed the time
frame in this question to be consistent with the
duration of follow-up [20]. One of the 11 samples
reported by Walters and Brazier likewise showed a
signiﬁcant difference between the “somewhat worse”
and “somewhat better” groups. This highlights a
potential problem in using Question 2 from the SF-36
for calculating the MID, as combining results for the
two groups assumes they are identical except for sign
[20]. Several issues may contribute to our result: the
appropriateness of the retrospective SF-36 Question 2
as a valid external criterion of change in health state,
the mismatch of time periods in the retrospective and
prospective SF-36 assessment in this study, and the
effect of response shift. Nevertheless, this article pro-
vides the ﬁrst published estimates of MID for the SCI
population using Walter and Brazier’s methodology.
There is debate as to whether preference weights
should be sourced from community samples or
directly from participants in a clinical trial [5,31].
Problems can arise when community preference
weights attribute artiﬁcially low utility scores to
disease groups like SCI, which may discriminate
against people with SCI by valuing their years of life
less highly, and therefore valuing health interventions
for them less favorably. On the other hand, response
shift in our directly measured sample probably con-
tributed to higher than expected values in some
dimensions. It is important that additional studies
with longitudinal data are performed within the SCI
population to further clarify responsiveness and the
effects of response shift, and to compare SCI utility
values derived from SF-6D and other methods with
those of other population groups.
Conclusion
The SF-6D can reliably discriminate not only the gross
differences between persons with SCI and a normative
population group, but also the smaller and more
clinically relevant differences between patients with
paraplegia and tetraplegia. The SF-12 and SF-36 vari-
ants of the SF-6D are both responsive to the additional
disease burden of UTI in this patient group. The MID
is consistent with published estimates for other disease
groups. The content of the SF-6D makes it more
appropriate than the SF-36 for use in this physically
impaired population.
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